Pay dips, but pension values soar for Lilly’s top execs
The top five executives at Eli Lilly and Co. took home 5 percent to 10 percent less in cash, stock and perks last year than the year before, according to a Monday securities filing.
Eli Lilly and Co.
Articles
Potential Alzheimer’s drug further backs protein hypothesis
The results of an experimental drug for Alzheimer’s disease provide the best evidence so far that the memory-robbing condition is caused by an errant protein in the brain. Drugmakers including Eli Lilly have been concentrating their Alzheimer’s research on that area.
Lilly joins $100M global Alzheimer’s venture fund
Major drugmakers—including Indianapolis-based Eli Lilly and Co.—the British government and a top Alzheimer's research charity are pooling more than $100 million to create a global fund to accelerate efforts to find a treatment or cure.
Sponsorship of diabetic NASCAR driver may help Lilly regain market share
21-year-old Ryan Reed stunned racing gurus on Feb. 21 by winning his first NASCAR race on stock-car racing’s most hallowed grounds. He did it with a wireless device attached to his stomach feeding a constant stream of data to a dashboard-mounted glucose monitor.
Warnings ordered on testosterone drugs like Lilly’s Axiron
Makers of testosterone drugs must change the products’ labels to clarify that they are approved for only certain disorders, not to help men deal with aging, U.S. regulators said.
Lilly to introduce Lantus copy in Europe after patent expires
Paris-based drugmaker Sanofi had revenue of $8.4 billion from Lantus last year. It lost U.S. patent protection this month and will lose exclusive rights in Europe in May.
Lilly to delay U.S., EU approval of basal insulin
Although the experimental diabetes drug is in final-stage testing and showing promising results, Lilly wants to better understand its effect on liver fat.
Feds finally end probe into Lilly bribery allegations
The U.S. Department of Justice told Lilly last month its investigation was over—more than a year after the drugmaker paid $29 million to the SEC to settle related bribery allegations.
Former Lilly partner ordered to pay $2.3M to Actos user
Takeda Pharmaceutical Co. was ordered by a jury Thursday to pay more than $2.3 million in damages to a former teacher who blamed the company’s Actos diabetes drug for causing his bladder cancer.
How Eli Lilly CEO Lechleiter pulled company out of long slide
After weathering a barrage of patent expirations, the pharmaceutical giant has restocked its pipeline and is positioned to grow.
Cuban immigrant gets 6 years for theft of Lilly drugs
A Cuban immigrant was sentenced Wednesday to more than six years in prison for his role in the 2010 heist of a Connecticut warehouse in which the robbers filled a tractor-trailer with more than $50 million worth of Eli Lilly and Co. pharmaceuticals.
Lilly’s profit, sales forecast falls
Eli Lilly and Co. predicted its 2015 sales will come in roughly $1 billion less than analysts have expected, due to the strength of the U.S. dollar against foreign currencies.
Novartis expects price war with Lilly over psoriasis drugs
Novartis AG is racing to establish itself in the market for new treatments for psoriasis ahead of competing drugs by Amgen Inc. and Eli Lilly and Co. in the United States.
Lilly sees insurers pushing harder for discounts
Health-coverage managers are becoming more aggressive in demanding discounts and exclusive deals from drugmakers to drive down the cost of medicine, Eli Lilly and Co.’s diabetes business chief says.
UPDATE: Lilly says it couldn’t have made tainted Cialis
A batch of Cialis pills, purportedly made at a plant in Australia, was banned by the FDA from entering the U.S. after the pills were found to contain the active ingredient for rival drug Viagra. Cialis manufacturer Eli Lilly said it doesn’t make any drugs in Australia.
UPDATE: Lilly forecasts earnings below analyst expectations
The Indianapolis-based drugmaker said its long-term strategy is on track, but predicted sales this year would be $20.3 billion to $20.8 billion, a shade below what Wall Street was expecting.
Lilly to sell heartworm line for Novartis deal approval
Eli Lilly and Co. wants to combine Novartis with its own animal health business, Elanco, to create the second-largest animal health company in the U.S.
Lilly reaches insulin development deal with Adocia
Eli Lilly and Co. could pay more than $570 million to French pharmaceutical company Adocia under an agreement to develop a fast-acting insulin that is in the early stages of clinical testing.
Lilly bumps up dividend for first time since 2009
Shares of Eli Lilly and Co. were on the rise Tuesday morning, a day after the drugmaker announced its first dividend increase in more than five years.
Lilly’s Cyramza gets new marketing approval
Eli Lilly and Co.'s drug Cyramza has been approved as a treatment for lung cancer, regulators said. The Food and Drug Administration is allowing Lilly to market the drug as a treatment for cases that have spread.